Published: Dec 22, 2020
ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced it has received approval from the Institutional Review Board (IRB) at Washington University School of Medicine in St. Louis (Washington University), to commence the Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients. As a result, the Company expects to commence patient enrollment for the Phase 1b/2a clinical trial in the first quarter of 2021.
Does Acupuncture Really Work? discovermagazine.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from discovermagazine.com Daily Mail and Mail on Sunday newspapers.
Below is Alston & Bird’s
Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and congressional committee action; reports, studies, and analyses; and other health policy news.
Week in Review Highlight of the Week:
On Wednesday, HHS finalized its review of Phase 3 Provider Relief Fund applications and began distribution of the funds. Read more about this action and other news below.
I. Regulations, Notices & Guidance
On December 14, 2020, the Department of Health and Human Services (HHS), along with several other agencies, issued a final rule entitled,
Equal Participation of Faith-Based Organizations in the Federal Agencies’ Programs and Activities. This rule provides clarity about the rights and obligations of faith-based organizations participating in the Agencies’ Federal financial assistance programs and activities. This rulemaking is intended to ensure that the Agencies’ Fed
Online petition calls on BJC to change COVID-19 vaccine plan doctors said puts older workers ahead of frontline employees
Doctors told 5 On Your Side the plan did not prioritize health care workers on the front lines, now an online petition is calling for BJC to make a change Author: Christine Byers (KSDK), Rhyan Henson Published: 9:06 PM CST December 20, 2020 Updated: 3:36 PM CST December 21, 2020
ST. LOUIS Some members of the medical staff at Barnes Jewish Hospital who say the administration’s vaccine rollout plan is leaving young frontline workers at risk have launched an online petition to protest the policy and demand it be changed.
P=0.02), the authors added.
“Radiation exposure of arterial vessels alters the natural history of coronary artery disease by inducing inflammation that subsequently triggers accelerated progression if the disease,” Atkins and colleagues explained and added,”Our study suggests that LAD coronary artery V15 Gy greater than or equal to 10% is an independent factor associated with MACE and all-cause mortality in patients with NSCLC.”
The analysis included patients who were treated with 3-D conformal radiotherapy or intensity-modulated radiotherapy techniques between December 2001 and January 2014. The median age was 65 years (interquartile range, (IQR), 57-73 years) and almost two-thirds of patients at 64.1% were at high CHD risk according to Framingham criteria. The median follow-up was 20.4 months (IQR, 8.2-44.6 months) and 47.8 months (IQR, 31.6-75.4) months in patients who were still alive at the time of study analysis.